Project/Area Number |
13670185
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Human pathology
|
Research Institution | Nagoya City University |
Principal Investigator |
INAGAKI Hiroshi Nagoya City University, Graduate School of Medical Sciences, Associated Professor, 大学院・医学研究科, 助教授 (30232507)
|
Project Period (FY) |
2001 – 2002
|
Project Status |
Completed (Fiscal Year 2002)
|
Budget Amount *help |
¥3,400,000 (Direct Cost: ¥3,400,000)
Fiscal Year 2002: ¥1,300,000 (Direct Cost: ¥1,300,000)
Fiscal Year 2001: ¥2,100,000 (Direct Cost: ¥2,100,000)
|
Keywords | MALT lymphoma / API2-MALT1 fusion / multiplex RT-PCR / clinicopathologic study / lung / thymus / skin / BCL10 |
Research Abstract |
API2-MALT1 fusion gene, cloned from t(11;18)(q21;q21) chromosomal translocation, is a gene abnormality specific to extranodal marginal zone B-cell lymphoma of mucosal-associated lymphoid tissue (MALT). However, the clinicopathologic significance of this chimeric gene remains to be clarified. We have developed a very sensitive multiplex RT-PCR assay for the API2-MALT1 fusion transcript using paraffin materials as a source of RNA, and enabled a large cohort study on this gene abnormality. Our data of a large series of pulmonary MALT lymphoma suggest that the API2-MALT1 fusion may be a causative gene abnormality unrelated to autoimmune disease. In addition, this alteration may define a homogeneous MALT lymphoma subtype that is clinically more indolent and histologically more "typical". Our observation that API2-MALT1 fusion is independence of autoimmune disease is further supported by the data obtained from the study of thymic MALT lymphoma. Aberrant nuclear BCL10 expression may have a possible role as a tool to screen for this API2-MALT1 fusion in pulmonary MALT lymphoma, but this is not the case with cutaneous MALT lymphoma. Case of rare esophageal and ureteral MALT lymphomas have been reported.
|